Novavax Inc says its experimental COVID-19 vaccine is safe and nearly 90% effective at preventing infection, an interim analysis shows.

On Thursday, the Gathersburg, Maryland-based company released results from two clinical trials, one held in the UK and the other in South Africa.

Both countries have seen highly infectious variants crop up in recent months that have spread around the world. 

A third clinical trial being conducted in the U.S. is still in the process of recruiting participants and is not expected to reveal data for several months.

In the UK late-stage trial, just 62 of more than 15,000 participants fell ill, showing 89.3 percent efficacy.  

Roughly half were infected with the UK variant known as B.1.1.7, and the vaccine appeared to be almost as effective in that group.

Results showed 95.6 percent efficacy the originally circulating variant and 85.6 percent against B 1.1.7. 

But in South Africa, the Novavax shot was not as protective and was found to be just 49.4% effective against COVID-19.

In a late-stage UK study, the Novovax vaccine was shown to be 89.3% effective at preventing COVID-19 infection, but it was just 49.3% effective against the South Africa variant. Pictured: Three potential coronavirus vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland, March 20

In a late-stage UK study, the Novovax vaccine was shown to be 89.3% effective at preventing COVID-19 infection, but it was just 49.3% effective against the South Africa variant. Pictured: Three potential coronavirus vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland, March 20

Novavax's vaccine uses synthesized pieces of the surface protein that the coronavirus uses to invade human cells and spurs antibody production. Pictured: The Novavax logo is reflected in a drop on a syringe

Novavax’s vaccine uses synthesized pieces of the surface protein that the coronavirus uses to invade human cells and spurs antibody production. Pictured: The Novavax logo is reflected in a drop on a syringe

Novavax, which has not produced a vaccine before, made one of six vaccine candidates given funding for research the Trump’s administration’s Operation Warp Speed last summer.

Its shot that contains synthesized pieces of the surface protein that the coronavirus uses to invade human cells.

The idea is that the protein will cause human cells to spur production of antibodies to fight the infection. 

The biotechnology company has been running trials in Britain, South Africa, the U.S. and Mexico 

However, the U.S.-based, late-stage trial did not begin until December after Novavax had issues in scaling up the vaccine’s manufacturing.

This is a breaking news story and will be updated. 

Source: | This article originally belongs to Dailymail.co.uk

You May Also Like

Gay teenagers are more than twice as likely to suffer from insomnia, study suggests

Gay teenagers are more than twice as likely to have trouble sleeping…

Meet the Rwandan man who’s ‘lived in isolation for 55 years… because of his extreme fear of women’

A Rwandan man has allegedly lived in isolation for 55 years because…

I planned my dream wedding from a hospital bed after my ‘swollen’ belly turned out to be ovarian cancer: Here’s what I want everyone to know

A mum planned her dream wedding from her hospital bed after her…

Covid US: Omicron BA.2 ‘stealth’ variant is not as ‘scary’ as some believe, expert says

Dr Pavitra Roychoudhury (pictured), a bioinformatics expert at the University of Washington,…